Peptide
Survodutide
Glucagon's metabolic partner
A dual GLP-1/glucagon receptor agonist with strong effects on liver fat and body composition. Developed for metabolic and liver diseases.
Mechanisms
- GLP-1/Glucagon agonism
- Liver fat reduction
- Energy expenditure increase
Dosing
Typical dose
0.6–4.8mg
Timing
Weekly injection. Notable for significant liver fat reduction.